A Study of KM602 in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

KM602

Multiple dose levels of KM602 will be administered, including 0.01 mg/kg QW, 0.1 mg/kg QW, 0.6 mg/kg QW, 3 mg/kg QW, and 10 mg/kg QW. KM602 is administered intravenously once a week, and each cycle is 21 days.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Xuanzhu Biopharmaceutical Co., Ltd.

INDUSTRY

NCT05766527 - A Study of KM602 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter